NCT00830973 - The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer | Biotech Hunter

Enrollment

184

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

January 31, 2009

Conditions

Breast NeoplasmsTamoxifen

Interventions

OTHER

Poor Metabolism Status Follow Up Therapy Considerations

If the patient's CYP2D6 metabolism status is 'poor' then specialist pharmacist will discuss drug therapy alternatives to tamoxifen.

OTHER

CYP2D6 Inhibiting Drugs

If the patient after having a CYP2D6 test has any drugs that inhibit tamoxifen metabolism then specialist pharmacist will contact the physician for alternative drug therapies.

Trial Locations (1)

07417

Robert Epstein, Franklin Lakes